Shawn Tomasello is the CEO of Cabaletta Bio, Inc., a biotechnology company focused on developing transformative therapies. With an MBA from Harvard Business School and expertise in the field, she brings valuable knowledge to the table. She joined the company...

Shawn Tomasello is the CEO of Cabaletta Bio, Inc., a biotechnology company focused on developing transformative therapies. With an MBA from Harvard Business School and expertise in the field, she brings valuable knowledge to the table. She joined the company in July 2023 after being appointed to the Board of Directors, filling a newly created position. Her independence and experience make her a key player in guiding the company. In 2023, her total compensation was $611,462, including a salary of $597,417. Interestingly, she serves on several committees within the company, including the Compensation Committee and the new Science and Technology Committee, showcasing her commitment to research and development in biotechnology. Beyond her position as CEO, Tomasello's role suggests she is likely involved in strategic decisions related to company objectives and advancing its pipeline. Under her leadership, Cabaletta is positioned to pursue innovative developments that could change the landscape of biotechnology, aligning with her vision for the company’s future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Cabaletta Bio, Inc. CEOs

C

Shawn Tomasello

CEO of Cabaletta Bio, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

May 15, 1978 - 47 years ago

CEO of Cabaletta Bio, Inc. for

1 year 10 months (Jul 2023 - Present)

Previous Experience

Former COO at XYZ Biotech

Rivals

Competitors/colleagues of Shawn Tomasello

Holdings

See how much did Shawn Tomasello make over time.

As of her appointment, Shawn Tomasello holds significant shares in Cabaletta Bio, Inc. She has options to purchase 44,000 shares at an exercise price of $13.48, which will vest over three years, reflecting the company's belief in her long-term leadership....

As of her appointment, Shawn Tomasello holds significant shares in Cabaletta Bio, Inc. She has options to purchase 44,000 shares at an exercise price of $13.48, which will vest over three years, reflecting the company's belief in her long-term leadership. This is a strategic move for both herself and the company, tying her financial success to the company's performance. Although specific values of her holdings aren't provided, the structure of her compensation implies she has a vested interest in Cabaletta's growth and innovations. Her shares and options are a key aspect of her alignment with shareholder interests, as her wealth is closely linked to the company’s success.

Insider Trading

See recent insider trades of Shawn Tomasello.

No insider trades found for this CEO.

Compensation History

See how much did Shawn Tomasello make over time.

Shawn Tomasello's total compensation for 2023 is $611,462, primarily derived from her salary of $597,417. Notably, she did not receive any bonuses or stock grants this year. Her compensation package reflects the company's performance metrics, focusing on achieving specified company objectives and milestones. As she steps into her role as CEO, it’s essential that her compensation aligns with the exceptional goals of the company. By doing this, Tomasello shows her commitment to the company's mission and vision, motivating herself and the team to strive for success.

Year

2023

Total Compensation

$611.46K

Salary

$597.42K

Board Justification

The compensation committee reviews compensation annually based on market comparisons, individual performance, and company performance metrics.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023.

Other

$14.05K

Board Justification

Includes reimbursements for life insurance premiums.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023.

Performance Metrics

Company performance was assessed as achievement of 2023 company objectives, including certain pipeline and development milestones.

Other Cabaletta Bio, Inc. CEOs

Here are other CEOs of Cabaletta Bio, Inc.

Catherine Bollard

Ex-CEO of Cabaletta Bio, Inc.

June 2021 - July 2023